Eczema (Atopic Dermatitis)

Eczema (Atopic Dermatitis)

Atopic dermatitis is a chronic, relapsing inflammatory skin disease that affects 15 to 20 percent of children and 1 to 3 percent of adults worldwide. Its defining feature is a two-part failure: a structurally leaky epidermal barrier and a Th2-skewed immune response that keeps returning to the same sites. Five ingredients carry an evidence grade against it here, three at Grade B and two at Grade C, drawn from 66 studies and roughly 7,800 participants. That rating spread is itself informative, because the ingredients with the widest trial base are the ones acting on immune signalling and barrier lipids rather than on itch directly.

The barrier defect is often genetic. Loss-of-function mutations in filaggrin reduce the natural moisturizing factor that holds water in the stratum corneum, and the lipid bilayer between corneocytes is depleted of the ceramides that normally slow evaporation. Transepidermal water loss rises, allergens and microbes cross more easily, and the resulting inflammation degrades the barrier further. Intense pruritus, dry and scaly skin, weeping and crusting in acute flares, and lichenification in chronic disease follow from that loop, along with the sleep disturbance that patients frequently rate as the heaviest burden.

Lactobacillus rhamnosus holds the largest evidence base in this set, with 20 studies and about 3,500 participants supporting a Grade B rating. The strain most often studied is Lactobacillus rhamnosus GG, whose pediatric use has been reviewed in detail ^[1]. Trials cluster around infancy and early childhood, which is where the barrier and the immune repertoire are still being established, so the finding does not transfer automatically to adult disease.

Omega-3 fatty acids and vitamin D share the same Grade B rating on smaller bases, 14 studies and 1,200 participants for omega-3 and 12 studies and 1,800 participants for vitamin D. Both are plausible on mechanism: long-chain omega-3s shift eicosanoid production away from pro-inflammatory mediators, and vitamin D regulates antimicrobial peptide expression and keratinocyte differentiation in skin ^[2]. Reviews of nutrition in atopic dermatitis place both among the better-supported dietary factors while noting that serum status at baseline strongly conditions any observed response ^[3].

Evening primrose oil and borage oil sit at Grade C with a direction recorded as mixed, across 12 studies and 800 participants and 8 studies and 500 participants respectively. Both supply gamma-linolenic acid, and the rationale rested on a reported deficit in delta-6-desaturase activity in atopic skin. A Cochrane review of dietary supplements in established atopic eczema found the accumulated evidence insufficient to support their use, which is the honest reading of a mixed direction rather than a null one ^[4].

Two limits apply across the whole set. Trial outcomes are usually severity indices scored by clinicians, which respond to seasonal and behavioural change as well as to any supplement, and follow-up rarely extends past a few months in a disease measured in decades. Nothing in this evidence base displaces emollient therapy, trigger avoidance, or the topical and systemic treatments a dermatologist prescribes; the graded ingredients are studied as adjuncts, and severe or infected eczema warrants medical assessment.